Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Euro-Med Laboratories Philippines's Equity-to-Asset or its related term are showing as below:
PHS:EURO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53 Med: 0.56 Max: 0.6
Current: 0.57
During the past 13 years, the highest Equity to Asset Ratio of Euro-Med Laboratories Philippines was 0.60. The lowest was 0.53. And the median was 0.56.
PHS:EURO's Equity-to-Asset is ranked worse than 54.82% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs PHS:EURO: 0.57
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Euro-Med Laboratories Philippines Equity-to-Asset Related Terms
Euro-Med Laboratories Philippines Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHS:EURO vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euro-Med Laboratories Philippines's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euro-Med Laboratories Philippines Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euro-Med Laboratories Philippines's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Euro-Med Laboratories Philippines's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euro-Med Laboratories Philippines (PHS:EURO) has a Equity-to-Asset of 0.57 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Euro-Med Laboratories Philippines and its competitors. This is near median its historical median of 0.56. Over the past decade, Euro-Med Laboratories Philippines' Equity-to-Asset has ranged from 0.53 to 0.60. According to the industry distribution chart, Euro-Med Laboratories Philippines ranks #552 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 54.8%.
Is Euro-Med Laboratories Philippines' Equity-to-Asset too high?
Euro-Med Laboratories Philippines' current Equity-to-Asset of 0.57 is near median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 0.60. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Euro-Med Laboratories Philippines' value of 0.57 is 5% below this industry median. Based on the distribution chart, Euro-Med Laboratories Philippines ranks #552 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Euro-Med Laboratories Philippines has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Euro-Med Laboratories Philippines' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euro-Med Laboratories Philippines ranks #552 out of 1007 companies for Equity-to-Asset. This places Euro-Med Laboratories Philippines in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Euro-Med Laboratories Philippines' value of 0.57 is 5% below this benchmark. Historically, Euro-Med Laboratories Philippines' own Equity-to-Asset has ranged from 0.53 to 0.60 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 0.60, Euro-Med Laboratories Philippines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euro-Med Laboratories Philippines's current Equity-to-Asset of 0.57 is 5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Euro-Med Laboratories Philippines and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euro-Med Laboratories Philippines's current Equity-to-Asset is 0.57, which is near median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euro-Med Laboratories Philippines stock overvalued right now?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines (PHS:EURO) is currently considered Fairly Valued. The stock's GF Value™ is ₱1.07, compared to a current price of ₱1.15 — trading 7.5% above its estimated fair value. The current Equity-to-Asset is 0.57, which is near median its 10-year median of 0.56 and 5% below the Drug Manufacturers industry median of 0.60. Euro-Med Laboratories Philippines' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Euro-Med Laboratories Philippines (PHS:EURO), the current Equity-to-Asset is 0.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euro-Med Laboratories Philippines (PHS:EURO) Overvalued in 2026?
Based on GuruFocus' analysis, Euro-Med Laboratories Philippines stock appears to be overvalued.
The current stock price of ₱1.15 is trading 7.5% above its estimated GF Value™ of ₱1.07.
GuruFocus considers Euro-Med Laboratories Philippines to be Fairly Valued.
Key valuation signals for PHS:EURO:
Equity-to-Asset: 0.57 (near median its 10-year median of 0.56)
GF Value™: ₱1.07 vs. price of ₱1.15 (7.5% above fair value)
Industry Position: 5% below the Drug Manufacturers median (#552 of 1007)
No single metric tells the full story. See the PHS:EURO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euro-Med Laboratories Philippines Inc is a pharmaceutical-based company that engages in the manufacture of pharmaceutical products such as large and small-volume parenterals and other solutions. The company also manufactures sterile water for injection, and other solutions such as ophthalmic, inhalation, irrigation, and dialysis. The Company also manufactures intravenous fluids in glass bottles, hemodialysis concentrates, ophthalmic products and disinfectants.
80GF Score
Get the complete analysis for PHS:EURO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHS:EURO has been successfully added to your 
